| Thursday | November 10 |
|---|---|
| Coffe and sandwich will be served from 08.30 | |
| 09.00-11.00 | Registration |
| 11.00 | Satellite symposium 1 – Janssen Current and emerging therapies in Crohn’s disease Introduction (Jonas Halfvarson) |
| 11.10 | Unmet medical needs in Crohn’s disease management (Michael Eberhardsson) |
| 11.30 | Emerging therapies (Laurent Peyrin-Biroulet) |
| 11.50 | Q&A and discussion |
| 12.00 | Lunch |
| 13.00 | Opening of the meeting Tom Øresland |
| Session 1 Moderators: Olof Grip and Tom Øresland |
|
| 13.05 | The interface of IBS and IBD (Hans Strid) |
| 13.25 | The microbiome and mucosal immunity in IBD (Maria Abreu) |
| 13.45 | Stem cell transplantation (Chris Hawkey) |
| 14.05 | Extraintestinal problems in IBD, how to treat, can they be avoided? (Johannes R Hov) |
| 14.25 | Quality of Care (L. Peyrin-Biroulet) |
| 14.45 | Coffee break |
| Session 2 – Treatment strategies Moderators: Torben Knudsen and Stefan Lindgren |
|
| 15.15 | Do biosimilars change our strategies? (Bjørn Moum) |
| 15.35 | Combination treatments – benefits and risks (L. Peyrin-Biroulet) |
| 15.55 | Second line therapies in acute ulcerative colitis (Eduard Stange) |
| 16.15 | How to optimize anti-TNF therapy (Iris Dotan) |
| 16.35 | Minimizing risks of biologicals (Iris Dotan) |
| 17.00 | Satellite symposium 3 – AbbVie IBD2020 – Improving Quality of Care in IBD (Stefan Lindgren, Iris Dotan, Jonas Halfvarson) |
| 18.00 | Adjurn |
| 20.00 | Dinner at Hotel Hilton Slussen Stockholm |
| Friday | November 11 |
|---|---|
| Coffe and sandwich will be served from 07.30 | |
| 08.00 | Satellite symposium 4 – Takeda Long-Term Management and Real World Experience with Vedolizumab in IBD Moderator: Jonas Halfvarson |
| 08.10 | Aiming for long-term remission for patients with moderate to severe Crohn´s disease – how to use personalized medicine and when to switch mode of action (Michael Eberhardson) |
| 08.30 | Real world experience with vedolizumab in Crohn´s disease and ulcerative colitis (Gert van Assche) |
| 08.50 | Discussion and conclusions (Jonas Halfvarson) |
| 09.00 | Presentation of five selected posters Moderator Tom Øresland |
| Session 3 Moderators: Marie Carlson and Bjørn Moum |
|
| 09.30 | Biologicals, how good are they? |
| The story from trials (Eduard Stange) | |
| The real world story (Gert Van Assche) | |
| 10.10 | Coffee break |
| 10.50 | The IBD exposome and genome (Séverine Vermeire) |
| 11.10 | Evolving trends in IBD surgery (Pär Myrelid) |
| 11.30 | Tandem Talk: Novel therapies in IBD, the immunologist meets the gastroenterologist (Ola Winqvist, Jonas Halfvarson) |
| 12.10 | Lunch |
| Session 4 Moderators: Olof Grip and Torben Knudsen |
|
| 13.10 | Fecal transplantation – a blind end? (Séverine Vermeire) |
| 13.30 | Iron and IBD – what we need to know (Stefan Lindgren) |
| 13.50 | SWIBREG – What’s in it, how can we use it? (Pär Myrelid) |
| 14.10 | Biomarkers for diagnosis and monitoring (Jonas Halfvarson) |
| 14.30 | Coffee break |
| Session 5 Moderators: Marie Carlson and Jonas Halfvarson |
|
| 15.00 | How to define endoscopic activity in IBD (Gert Van Assche) |
| 15.20 | The use of biologicals during pregnancy and lactation (Maria Abreu) |
| 15.55 | Best poster award (Olof Grip, Jonas Halfvarson) |
| 16.00 | Adjurn |